Table 2:
Individual patient data
| Subject | Sex | Age (years) | Disease Duration (months) | Organs Affected | Serum IgG4 (mg/dL) |
Serum IgE (IU/mL) |
Concurrent Prednisone Treatment | Complete Remission (Week 24) | Disease Response (Week 12) | Disease Response (Week 24) | ABA doses received (#) | Previous Treatment History | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (Baseline) | (Week 24) | (Baseline) | (Week 24) | |||||||||||
| 1 | F | 63 | 84 | Lacrimal, salivary, pancreas | 170 | NA | 127 | NA | No | No | No | No | 6 | Prednisone & RTX |
| 2 | M | 65 | 240 | Lungs, PVM, RPF, orbit, salivary | 787.4 | NA | 544 | NA | Yes | No | No | No | 7 | Prednisone, RTX, & ocrelizumab |
| 3 | M | 66 | 68 | Orbit, lungs, salivary, ENT, LN | 591.2 | 811.6 | 807 | 593 | No | Yes | Yes | Yes | 24 | Obexelimab, prednisone & RTX |
| 4 | M | 76 | 27 | Lungs, aorta, RP, pancreas | 298.4 | 163.3 | 802 | 470 | No | Yes | Yes | Yes | 24 | Prednisone & obexelimab |
| 5 | F | 73 | 25 | Orbit, lungs, salivary | 1359.5 | 1441.3 | 324 | 187 | No | No | Yes | Yes | 24 | RTX |
| 6 | M | 48 | 42 | Orbit, skin, salivary, LN, lungs | 602.7 | NA | 527 | NA | No | No | No | No | 12 | Prednisone & RTX |
| 7 | M | 69 | 52 | Lacrimal, salivary, pancreas, bile duct, kidney | 346.3 | 428.7 | 9,154 | 4,241 | No | Yes | Yes | Yes | 24 | Prednisone & RTX |
| 8 | F | 40 | 1 | Orbit, lungs, Salivary, ENT, LN | 304 | NA | 174 | NA | No | No | Yes | No | 12 | None |
| 9 | M | 69 | 2 | Lacrimal, salivary, kidney | 912.7 | NA | 434 | NA | Yes | No | No | No | 8 | None |
| 10 | M | 79 | 3 | Orbit, lung, lacrimal, salivary, pancreas | 1199.4 | 495.2 | 195 | 88 | Yes | No | Yes | Yes | 24 | None |
Key: ABA= abatacpet; RTX = rituximab; PVM = paravertebral mass; RPF = retroperitoneal fibrosis; LN = lymph node; ENT = ears, nose, throat